The present invention relates to a peptide selectively binding to a cancer cell-derived exosome, and uses thereof, wherein a peptide of ExoPep (CRKVAKG) has been discovered using a phage display technique to discover a peptide with specific binding ability to an exosome derived from cancer cells, and the peptide binds to a cancer cell-derived exosome having a property of moving to a cancer site and a cancer metastasis site, and thus may have the effect of delivering an anticancer drug to the cancer metastasis site.

The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.

In some aspects, a method of regulating oxidoreductase activity for treating an inflammation or age-related disorder involves administering to an individual isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, a method of treating oxidative stress associated with an inflammation or age-related disorder involves administering to an individual a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of infectious or parasitic diseases or various other disorders.

The present invention provides an agent for the treatment or prophylaxis of a neurodegenerative disease, containing an apoptosis inhibitor of macrophage (AIM), an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment.

The present invention discloses a novel engineered peptides P3T, P7T, P8T, P9T, P13T and P8_d1 of Seq ID No. 1 to combinations comprising one or more said peptides and compositions comprising one or more said peptides with pharmaceutically acceptable carriers and excipients and their use. The peptides and composition comprising said peptides induce autophagy by binding the protein GAPR-1 (−ve regulator of autophagy). Endogenously, GAPR-1 acts by tethering critical autophagy protein Beclin-1 (+ve regulator of autophagy) at the golgi and arrest autophagy. The peptide reported here binds GAPR-1 to free Beclin-1 and subsequently induce autophagy. The peptide can be used to induce or enhance autophagy and finds therapeutic application in a broad spectrum of disease pathologies that benefit from augmented autophagy, including obesity, diabetes, NASH, cancer, cardiomyopathy, neurodegenerative diseases, IBD and pathogenic infections.

The disclosure relates to fusion proteins comprising a tBID polypeptide and a steroid hormone receptor domain, and methods of using same to induce apoptosis in cells.

The disclosure relates to methods, cells, and compositions for preparing cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods for expansion and proliferation of primary immune cells including T cell populations.

The current invention relates to a chimeric polypeptide, a nucleic acid encoding such chimeric polypeptide, a cell comprising such chimeric polypeptide of nucleic acid, preferably a T cell, a CAR T cell, NK cell or a CAR NK cell, and method of treatment using such cell, polypeptide of nucleic acid in the treatment of cancer, in particular in immune cell therapy. The chimeric polypeptide according to the invention allows for the reversible and dose dependent control of T cell and NK cell function (cytokine release, cytotoxicity).

Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.

Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.